FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Raoul Tibes

Research Profile

Chemicals & Drugs

Disorders

Physiology

Concepts & Ideas

Devices

Protein Array Analysis

Anatomy

Tumor Cell Line

Co-author Network

Publications

TOP 3
Raoul Tibes; Mohammad Azab; Gavin Choy; Gil Fine; Aram Oganesian; Sanjeev Redkar; Amarpal Sahai; Pietro Taverna; Anthony W Tolcher
A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors.
Gayle S Jameson; Robert Jotte; Robert Medve; Ramesh K Ramanathan; Lee S Rosen; Katrina Schroeder; Raoul Tibes; Carlos Alemany; Stephen Anthony; Michele Basche; Mitesh J Borad; Allen Cohn; Michael A Eldon; John T Hamm; Ioana Hinshaw; Ute Hoch; Glen J Weiss; Erica White; Daniel D Von Hoff
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
Raoul Tibes; James M Bogenberger; Ruben A Mesa
JAK inhibition: the key to treating myeloproliferative neoplasm?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Raoul Tibes (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Raoul Tibes; Mohammad Azab; Gavin Choy; Gil Fine; Aram Oganesian; Sanjeev Redkar; Amarpal Sahai; Pietro Taverna; Anthony W Tolcher
A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2013;71(2):463-71.
2013: Gayle S Jameson; Robert Jotte; Robert Medve; Ramesh K Ramanathan; Lee S Rosen; Katrina Schroeder; Raoul Tibes; Carlos Alemany; Stephen Anthony; Michele Basche; Mitesh J Borad; Allen Cohn; Michael A Eldon; John T Hamm; Ioana Hinshaw; Ute Hoch; Glen J Weiss; Erica White; Daniel D Von Hoff
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(1):268-78.
2012: Raoul Tibes; James M Bogenberger; Ruben A Mesa
JAK inhibition: the key to treating myeloproliferative neoplasm?
Expert review of hematology 2012;5(6):583-5.
2012: Ruben A Mesa; Raoul Tibes
MPN blast phase: clinical challenge and assessing response.
Leukemia research 2012;36(12):1496-7.
2012: Raoul Tibes; James M Bogenberger; Holly L Geyer; Ruben A Mesa
JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Expert opinion on investigational drugs 2012;21(12):1755-74.
2012: Glen J Weiss; Lisa Blaydorn; Mitesh J Borad; Marina Ciomei; francesco Fiorentini; Manuel Hidalgo; Jeffrey D Isaacs; Gayle Jameson; Antonio Jimeno; Daniel Laheru; Maria Adele Pacciarini; Ramesh K Ramanathan; Angela Scaburri; Raoul Tibes; Daniel D Von Hoff
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Investigational new drugs 2012;30(6):2334-43.
2012: Curtis A Thacker; Raoul Tibes; Glen J Weiss; Erica White; Jason Baldwin; Lisa Blaydorn; Molly Downhour; Daniel D Hoff; Ronald L Korn
18-FDG PET/CT assessment of basal cell carcinoma with vismodegib.
Cancer medicine 2012;1(2):230-6.
2012: Raoul Tibes; Kasey L Benson; James M Bogenberger; Ruben A Mesa
Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Molecular diagnosis & therapy 2012;16(5):269-83.
2012: Chad Cherington; Veena Fauble; Ginger Gillette-Kent; Meagan S Higgins; Jose Leis; Roberta H Adams; Jeffrey Betcher; John K Camoriano; Joseph R Mikhael; Pierre Noel; Jane J Olsen; Mary E Peterson; Craig B Reeder; James L Slack; Raoul Tibes; Lisa D Tremblay; Ruben A Mesa
Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
Leukemia research 2012;36(9):1147-51.
2012: Raoul Tibes; Ruben A Mesa
Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques.
Leukemia research 2012;36(6):664-71.
2012: Holly L Geyer; Raoul Tibes; Ruben A Mesa
JAK2 inhibitors and their impact in myeloproliferative neoplasms.
Hematology (Amsterdam, Netherlands) 2012;17 Suppl 1():S129-32.
2012: Raoul Tibes; Hongwei H Yin; Shilpi Arora; James M Bogenberger; Esteban Braggio; Megan E Buechel; Leena Chaudhuri; Donald Chow; Tim Demuth; Irma M Gonzales; R Tanner Hagelstrom; Ruben A Mesa; James Slack; David Azorsa
RNAi screening of the kinome with cytarabine in leukemias.
Blood 2012;119(12):2863-72.
2012: Madappa N Kundranda; Raoul Tibes; Ruben A Mesa
Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Current hematologic malignancy reports 2012;7(1):78-86.
2012: Mitesh J Borad; Kelly K Curtis; Amylou Dueck; Gayle Jameson; Ramesh K Ramanathan; Raoul Tibes; Hani M Babiker; Martin Benjamin; Karen Wright; Daniel D Von Hoff
The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials.
Journal of Cancer 2012;3():345-53.
2011: Raoul Tibes; Daniel Von Hoff; Jay H Yim; R Curtis Bay; Martin A Benjamin; Raysenia L James; Barbara F Piper; Ramesh K Ramanathan; Jessica A Smith; Mitesh J Borad
Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials.
Cancer 2011;117(14):3276-83.
2011: Raoul Tibes; Ruben A Mesa
Blood consult: resistant and progressive essential thrombocythemia.
Blood 2011;118(2):240-2.
2011: Raoul Tibes; Ruben A Mesa
Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Leukemia & lymphoma 2011;52(7):1178-87.
2011: Geoffrey I Shapiro; Raoul Tibes; Michael S Gordon; Bryan Y Wong; Joseph Paul Eder; Mitesh J Borad; David S Mendelson; Nicholas J Vogelzang; Bruno R Bastos; Glen J Weiss; Cristian Fernandez; William Sutherland; Hitoshi Sato; William E Pierceall; David Weaver; Scott Slough; Ernesto Wasserman; Donald W Kufe; Daniel Von Hoff; Takumi Kawabe; Sunil Sharma
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(10):3431-42.
2011: Glen J Weiss; Jeffrey R Infante; E Gabriela Chiorean; Mitesh J Borad; Johanna C Bendell; Julian R Molina; Raoul Tibes; Ramesh K Ramanathan; Karen Lewandowski; Suzanne F Jones; Mario Lacouture; Virginia K Langmuir; Hank Lee; Stew Kroll; Howard A Burris
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(9):2997-3004.
2011: Patricia M LoRusso; Charles Rudin; Josina C Reddy; Raoul Tibes; Glen J Weiss; Mitesh J Borad; CHRISTINE HANN; Julie R Brahmer; Ilsung Chang; Walter C Darbonne; Richard A Graham; Kenn L Zerivitz; Jennifer A Low; Daniel Von Hoff
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(8):2502-11.
2010: Shivan H Amin; Raoul Tibes; Ji-Eon Kim; C Patrick Hybarger
Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma.
The Laryngoscope 2010;120(12):2456-9.
2010: Shilpi Arora; Kristen M Bisanz; Lourdes A Peralta; Gargi D Basu; Ashish Choudhary; Raoul Tibes; David Azorsa
RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.
Gynecologic oncology 2010;118(3):220-7.
2010: Shilpi Arora; Irma M Gonzales; R Tanner Hagelstrom; Christian Beaudry; Ashish Choudhary; Chao Sima; Raoul Tibes; Spyro Mousses; David Azorsa
RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.
Molecular cancer 2010;9():218.
2009: K M Eisenmann; K J Dykema; S F Matheson; N F Kent; A D DeWard; R A West; Raoul Tibes; Kyle A Furge; ARTHUR S ALBERTS
5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
Oncogene 2009;28(39):3429-41.
2009: Daniel Von Hoff; Patricia M LoRusso; Charles Rudin; Josina C Reddy; Robert L Yauch; Raoul Tibes; Glen J Weiss; Mitesh J Borad; CHRISTINE HANN; Julie R Brahmer; Howard M Mackey; Bertram L Lum; Walter C Darbonne; James C Marsters; Frederic J de Sauvage; Jennifer A Low
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
The New England journal of medicine 2009;361(12):1164-72.
2009: Steven M Kornblau; Raoul Tibes; Yi Hua Qiu; Wenjing Chen; Hagop M Kantarjian; Michael Andreeff; Kevin R Coombes; Gordon B Mills
Functional proteomic profiling of AML predicts response and survival.
Blood 2009;113(1):154-64.
2008: Raoul Tibes; Steven M Kornblau; Yihua Qiu; Spyro Mousses; Christiane Robbins; Tracy Moses; John D Carpten
PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation.
British journal of haematology 2008;140(3):344-7.
2007: Elihu Estey; Marcos De Lima; Raoul Tibes; Sherry Pierce; Andrew Lamb; Richard Champlin; Sergio Giralt
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Blood 2007;109(4):1395-400.
2006: Raoul Tibes; Yihua Qiu; Yiling Lu; Bryan T. J. Hennessy; Michael Andreeff; Gordon B Mills; Steven M Kornblau
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells.
Molecular cancer therapeutics 2006;5(10):2512-21.
2006: Raoul Tibes; Michael J Keating; Alessandra Ferrajoli; William G Wierda; Farhad Ravandi; Guillermo Garcia-Manero; Susan O'Brien; Jorge Cortes; Srdan Verstovsek; Mary L Browning; Stefan Faderl
Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Cancer 2006;106(12):2645-51.
2005: Raoul Tibes; Jonathan Trent; Razelle Kurzrock
Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.
Annual review of pharmacology and toxicology 2005;45():357-84.